A number of other research analysts have also issued reports on the stock. Barclays initiated coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They issued an overweight rating and a $55.00 target price on the stock. Zacks Investment Research lowered shares of ExlService from a hold rating to a sell rating in a report on Wednesday. Canaccord Genuity restated a speculative buy rating and issued a GBX 70 ($0.91) target price on shares of Bacanora Lithium in a report on Monday, July 1st. William Blair restated a buy rating on shares of Retrophin in a report on Friday, July 5th. Finally, ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Retrophin has a consensus rating of Buy and an average target price of $44.50.
NASDAQ RTRX traded up $0.27 during trading hours on Thursday, reaching $21.28. The company’s stock had a trading volume of 7,773 shares, compared to its average volume of 437,164. The company has a market cap of $872.31 million, a PE ratio of -8.33 and a beta of 0.93. Retrophin has a fifty-two week low of $17.53 and a fifty-two week high of $33.00. The business’s 50-day moving average price is $19.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.41). The business had revenue of $39.57 million during the quarter, compared to analyst estimates of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. Retrophin’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.14) earnings per share. As a group, equities research analysts forecast that Retrophin will post -3.02 earnings per share for the current year.
In other news, COO Neil F. Mcfarlane sold 1,968 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $18.25, for a total transaction of $35,916.00. Following the transaction, the chief operating officer now directly owns 27,972 shares in the company, valued at approximately $510,489. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Laura Clague sold 2,500 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $45,625.00. Following the transaction, the chief financial officer now owns 14,750 shares in the company, valued at $269,187.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,819 shares of company stock worth $194,503. 4.32% of the stock is owned by insiders.
Several hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC lifted its holdings in shares of Retrophin by 4.0% during the 4th quarter. Perceptive Advisors LLC now owns 3,342,038 shares of the biopharmaceutical company’s stock worth $49,782,000 after acquiring an additional 129,167 shares during the period. Macquarie Group Ltd. lifted its holdings in shares of Retrophin by 17.6% during the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock worth $51,278,000 after acquiring an additional 339,588 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Retrophin by 3.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,944,288 shares of the biopharmaceutical company’s stock worth $43,999,000 after acquiring an additional 73,284 shares during the period. Bank of America Corp DE lifted its holdings in shares of Retrophin by 114.4% during the 4th quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock worth $27,693,000 after acquiring an additional 652,895 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Retrophin by 6.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,154,859 shares of the biopharmaceutical company’s stock worth $26,134,000 after acquiring an additional 67,834 shares during the period.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.